PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsElvitegravir
Stribild(elvitegravir)
Genvoya, Stribild, Vitekta (elvitegravir) is a small molecule pharmaceutical. Elvitegravir was first approved as Stribild on 2012-08-27. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Combinations
Genvoya, Stribild
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir alafenamide fumarate
Tradename
Company
Number
Date
Products
GENVOYAGilead SciencesN-207561 RX2015-11-05
1 products, RLD, RS
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
STRIBILDGilead SciencesN-203100 RX2012-08-27
1 products, RLD, RS
Elvitegravir
Tradename
Company
Number
Date
Products
VITEKTAGilead SciencesN-203093 DISCN2014-09-24
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
genvoyaNew Drug Application2025-02-14
stribildNew Drug Application2025-02-04
stribild accessExport only2021-03-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
chronic hepatitis bEFO_0004239D019694B18.1
hiv—D006678O98.7
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Alafenamide Fumarate, Genvoya, Gilead Sciences Inc
100397182032-10-06DP
87540652032-08-15DS, DPU-257
92967692032-08-15DS, DPU-257
86332192030-04-30DPU-257
81483742029-09-03DS, DPU-1279
98912392029-09-03DPU-257
76357042026-10-26DS, DPU-257
89811032026-10-26DS, DP
71762202026-08-27DS, DPU-257
73907912025-01-07DS, DP
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AJ: Integrase inhibitors, antiinfectives for systematic use
— J05AJ02: Elvitegravir
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR09: Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
— J05AR18: Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
HCPCS
No data
Clinical
Clinical Trials
91 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20110306445
Acquired immunodeficiency syndromeD000163EFO_0000765B2017122320
HivD006678—O98.7—3103217
InfectionsD007239EFO_0000544——14117
Hepatitis cD006526—B19.2——21—3
Communicable diseasesD003141————1113
Chronic hepatitis cD019698EFO_0004220B18.2——11—2
CoinfectionD060085————11—2
HepatitisD006505—K75.9——11—2
Metabolic diseasesD008659EFO_0000589E88.9———1—1
Show 9 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Immunologic deficiency syndromesD007153—D84.9—511——12
Hiv-1D015497———11——2
Hepatitis bD006509————1——1
Renal insufficiencyD051437—N19——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-related side effects and adverse reactionsD064420—T88.711———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Insulin resistanceD007333EFO_0002614E88.8191————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Job syndromeD007589EFO_0003775D82.4————11
Drug misuseD000076064——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameElvitegravir
INNelvitegravir
Description
Elvitegravir is a quinolinemonocarboxylic acid that is 7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid substited at position 1 by a 1-hydroxy-3-methylbutan-2-yl group and at position 6 by a 3-chloro-2-fluorobenzyl group (the S-enantiomer). It is used in combination therapy for the treatment of HIV-1 infection. It has a role as a HIV-1 integrase inhibitor. It is a quinolinemonocarboxylic acid, an organofluorine compound, an aromatic ether, a quinolone and a member of monochlorobenzenes.
Classification
Small molecule
Drug classantivirals: integrase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C
Identifiers
PDB—
CAS-ID697761-98-1
RxCUI—
ChEMBL IDCHEMBL204656
ChEBI ID72289
PubChem CID5277135
DrugBankDB09101
UNII ID4GDQ854U53 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Genvoya – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Stribild – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,724 documents
View more details
Safety
Black-box Warning
Black-box warning for: Genvoya, Stribild, Stribild access
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
12,151 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use